News

Zacks.com on MSN2h
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly: 50% Upside For LLY Stock?
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...